Efficacy
DISEASE, SECONDARY
In the intent‐to‐treat analysis set, median PFS was 3.7 months (95% CI: 1.9, 5.3) in the pamiparib arm and 2.1 months (95% CI: 1.9, 3.8) in the placebo arm (Figure Kaplan–Meier plot of progression‐free survival per RECIST v1.1 in the intent‐to‐treat analysis set. PFS was estimated by the Kapan–Meier method, with 95% CIs estimated using the Brookmeyer–Crowley method. *Summary of secondary efficacy endpoints.
Abbreviations: CI, confidence interval; DoR, duration of response; NE, not evaluable; ORR, objective response rate; OS, overall survival; TSST, time to second subsequent treatment; TTR, time to response.OS and TSST were analyzed using the intent‐to‐treat analysis set; ORR, DoR, and TTR were analyzed using the efficacy evaluable analysis set.In the efficacy evaluable analysis set, between the pamiparib and the placebo arms, respectively: ORR was 7.7% (95% CI: 1.6, 20.9) [3 PRs] versus 6.3% (95% CI: 0.8, 20.8) [2 PRs], the rate of stable disease was 46.2% (18 patients) versus 37.5% (12 patients), median DoR was 3.6 months and not evaluable, and median TTR was 3.7 months (range: 1.8, 7.3) versus 1.9 months (range: 1.9, 1.9).